<p>Acadian Asset Management LLC 在第一季度通過與證券交易委員會的最新 13F 備案顯示，將其在 Agenus Inc.（納斯達克股票代碼：AGEN - 免費報告）的持股增加了 1,959.9%。該機構投資者在該時期購入了額外的 720,629 股，持有這家生物技術公司的 757,397 股股票。根據最新的 SEC 備案，Acadian Asset Management LLC 持有的 Agenus 股份價值 439,000 美元，佔 Agenus 約 3.73%。</p>
<p>許多其他大型投資者也對該公司的持股進行了調整。Vanguard Group Inc.在第三季度增加了其在 Agenus 的持股比例 1.6%。Vanguard Group Inc.現在擁有 26,938,439 股這家生物技術公司的股票，價值 30,440,000 美元，比上一季度增加了 432,202 股。SG Americas Securities LLC 在第四季度將其在 Agenus 的持股比例增加了 526.6%。SG Americas Securities LLC 現在擁有 198,735 股這家生物技術公司的股票，價值 165,000 美元，比上一季度增加了 167,017 股。Assenagon Asset Management S.A.在第四季度將其在 Agenus 的持股比例增加了 3,008.8%。Assenagon Asset Management S.A.現在擁有 2,306,248 股這家生物技術公司的股票，價值 1,909,000 美元，比上一季度增加了 2,232,064 股。PCG Wealth Advisors LLC 在第四季度將其在 Agenus 的持股比例增加了 65.7%。PCG Wealth Advisors LLC 現在擁有 47,550 股這家生物技術公司的股票，價值 39,000 美元，比上一季度增加了 18,850 股。最後，Cardinal Strategic Wealth Guidance 在第四季度將其在 Agenus 的持股比例增加了 28.2%。Cardinal Strategic Wealth Guidance 現在擁有 910,265 股這家生物技術公司的股票，價值 754,000 美元，比上一季度增加了 200,000 股。機構投資者持有該公司股份的比例為 61.46%。</p>
<h2>分析師評級變動</h2>
<p>許多股票分析師已經發布了關於 AGEN 股票的報告。HC Wainwright 將 Agenus 的評級從 “買入” 調降至 “中性”，並將股票的目標價格從 40.00 美元降至 9.00 美元。StockNews.com 在 4 月 17 日的報告中開始對 Agenus 進行覆蓋。他們為該公司設定了 “持有” 評級。Robert W. Baird 將 Agenus 的評級從 “表現優異” 調降至 “中性”，並將公司的價格目標從 35.00 美元降至 8.00 美元。William Blair 將 Agenus 的評級從 “表現優異” 調降至 “市場表現” 評級。最後，Jefferies Financial Group 重申了對 Agenus 的 “持有” 評級，並在 7 月 19 日的報告中將股票的目標價格從 3.00 美元上調至 7.00 美元。六位研究分析師對該股票進行了持有評級，一位給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，共識目標價格為 31.00 美元。</p>
<p><strong>查看我們對 AGEN 的最新股票分析</strong></p>
<h2>Agenus 股價表現</h2>
<p>納斯達克 AGEN 股票週五開盤價為 6.56 美元。Agenus Inc.的 52 周最低價為 4.78 美元，52 周最高價為 32.00 美元。該股的市值為 1.3775 億美元，市盈率為-0.51，貝塔係數為 1.32。該公司的 50 日移動平均價為 13.90 美元，200 日移動平均價為 12.52 美元。</p>
<p>Agenus（納斯達克：AGEN - 獲取免費報告）最近發佈了其財報，日期為 5 月 7 日。這家生物技術公司在該季度報告中每股虧損 3.04 美元，超過了每股虧損 3.58 美元的分析師預期。該公司在該季度的營收為 2,801 萬美元，低於分析師預期的 4,070 萬美元。賣方分析師平均預計，Agenus Inc.今年將實現每股盈利-10.73 美元。</p>
<h2>Agenus 簡介（免費報告）</h2>
<p>Agenus Inc.是一家臨牀階段的生物技術公司，致力於在美國和國際市場發現和開發免疫腫瘤學產品。該公司提供 Retrocyte Display，一種用於識別全人類和人源化單克隆抗體的抗體表達平台；以及展示技術。</p>
<h2>精選文章</h2>
<ul>
<li>我們比 Agenus 更喜歡的五支股票</li>
<li>除了喝咖啡，還有三種投資方式</li>
<li>為什麼這兩支股票的認購期權交易量會同時激增</li>
<li>什麼是認沽期權交易量？</li>
<li>MarketBeat 周評 - 7/22 - 7/26</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>3M 公司的業績出人意料並加速反彈：現在入市為時尚早</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 625,000% 收益（來自加密交易利潤）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODI4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODI4"/></p>
<h2>您現在是否應該投資 1,000 美元購買 Agenus 股票？</h2>
<p>在考慮購買 Agenus 股票之前，您可能需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高且表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而 Agenus 不在這份名單上。</p>
<p>儘管 Agenus 目前在分析師中的評級為 “持有”，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

安帝君斯

阿卡迪亞

<p>Acadian Asset Management LLC 根據最近向證券交易委員會提交的 13F 文件，在第一季度將其在 Agenus Inc.（納斯達克股票代碼：AGEN）的持倉增加了 1,959.9%。其他大型投資者也對該公司的持倉進行了調整。多家股票分析師發佈了關於 Agenus 的報告，一致給出 “持有” 評級，並設定了 31.00 美元的目標股價。Agenus Inc.的市值為 1.3775 億美元，市盈率為-0.51</p>

<p>Acadian Asset Management LLC lifted its position in Agenus Inc. (NASDAQ:AGEN - Free Report) by 1,959.9% in the first quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 757,397 shares of the biotechnology company's stock after buying an additional 720,629 shares during the period. Acadian Asset Management LLC owned about 3.73% of Agenus worth $439,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Acadian Asset Management LLC 在第一季度通過與證券交易委員會的最新 13F 備案顯示，將其在 Agenus Inc.（納斯達克股票代碼：AGEN - 免費報告）的持股增加了 1,959.9%。該機構投資者在該時期購入了額外的 720,629 股，持有這家生物技術公司的 757,397 股股票。根據最新的 SEC 備案，Acadian Asset Management LLC 持有的 Agenus 股份價值 439,000 美元，佔 Agenus 約 3.73%。</p>
</div><p>A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Agenus by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company's stock worth $30,440,000 after purchasing an additional 432,202 shares in the last quarter. SG Americas Securities LLC increased its holdings in Agenus by 526.6% during the 4th quarter. SG Americas Securities LLC now owns 198,735 shares of the biotechnology company's stock worth $165,000 after purchasing an additional 167,017 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Agenus by 3,008.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company's stock worth $1,909,000 after purchasing an additional 2,232,064 shares in the last quarter. PCG Wealth Advisors LLC increased its holdings in Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 18,850 shares in the last quarter. Finally, Cardinal Strategic Wealth Guidance increased its holdings in Agenus by 28.2% during the 4th quarter. Cardinal Strategic Wealth Guidance now owns 910,265 shares of the biotechnology company's stock worth $754,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors own 61.46% of the company's stock.</p>
<div class="lb-trans"><p>許多其他大型投資者也對該公司的持股進行了調整。Vanguard Group Inc.在第三季度增加了其在 Agenus 的持股比例 1.6%。Vanguard Group Inc.現在擁有 26,938,439 股這家生物技術公司的股票，價值 30,440,000 美元，比上一季度增加了 432,202 股。SG Americas Securities LLC 在第四季度將其在 Agenus 的持股比例增加了 526.6%。SG Americas Securities LLC 現在擁有 198,735 股這家生物技術公司的股票，價值 165,000 美元，比上一季度增加了 167,017 股。Assenagon Asset Management S.A.在第四季度將其在 Agenus 的持股比例增加了 3,008.8%。Assenagon Asset Management S.A.現在擁有 2,306,248 股這家生物技術公司的股票，價值 1,909,000 美元，比上一季度增加了 2,232,064 股。PCG Wealth Advisors LLC 在第四季度將其在 Agenus 的持股比例增加了 65.7%。PCG Wealth Advisors LLC 現在擁有 47,550 股這家生物技術公司的股票，價值 39,000 美元，比上一季度增加了 18,850 股。最後，Cardinal Strategic Wealth Guidance 在第四季度將其在 Agenus 的持股比例增加了 28.2%。Cardinal Strategic Wealth Guidance 現在擁有 910,265 股這家生物技術公司的股票，價值 754,000 美元，比上一季度增加了 200,000 股。機構投資者持有該公司股份的比例為 61.46%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of equities analysts have issued reports on AGEN shares. HC Wainwright cut Agenus from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lowered their target price for the stock from $40.00 to $9.00 in a report on Thursday, July 18th. StockNews.com started coverage on Agenus in a report on Wednesday, April 17th. They set a &#34;hold&#34; rating for the company. Robert W. Baird cut Agenus from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and decreased their price objective for the company from $35.00 to $8.00 in a report on Friday, July 19th. William Blair cut Agenus from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Thursday, July 18th. Finally, Jefferies Financial Group restated a &#34;hold&#34; rating and issued a $7.00 price objective (up previously from $3.00) on shares of Agenus in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and a consensus price target of $31.00.</p>
<div class="lb-trans"><p>許多股票分析師已經發布了關於 AGEN 股票的報告。HC Wainwright 將 Agenus 的評級從 “買入” 調降至 “中性”，並將股票的目標價格從 40.00 美元降至 9.00 美元。StockNews.com 在 4 月 17 日的報告中開始對 Agenus 進行覆蓋。他們為該公司設定了 “持有” 評級。Robert W. Baird 將 Agenus 的評級從 “表現優異” 調降至 “中性”，並將公司的價格目標從 35.00 美元降至 8.00 美元。William Blair 將 Agenus 的評級從 “表現優異” 調降至 “市場表現” 評級。最後，Jefferies Financial Group 重申了對 Agenus 的 “持有” 評級，並在 7 月 19 日的報告中將股票的目標價格從 3.00 美元上調至 7.00 美元。六位研究分析師對該股票進行了持有評級，一位給予了買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “持有”，共識目標價格為 31.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on AGEN</strong></p>
<div class="lb-trans"><p><strong>查看我們對 AGEN 的最新股票分析</strong></p>
</div><h2>Agenus Price Performance</h2>
<div class="lb-trans"><h2>Agenus 股價表現</h2>
</div><p>Shares of NASDAQ AGEN opened at $6.56 on Friday. Agenus Inc. has a fifty-two week low of $4.78 and a fifty-two week high of $32.00. The stock has a market capitalization of $137.75 million, a price-to-earnings ratio of -0.51 and a beta of 1.32. The business has a 50-day moving average of $13.90 and a 200-day moving average of $12.52.</p>
<div class="lb-trans"><p>納斯達克 AGEN 股票週五開盤價為 6.56 美元。Agenus Inc.的 52 周最低價為 4.78 美元，52 周最高價為 32.00 美元。該股的市值為 1.3775 億美元，市盈率為-0.51，貝塔係數為 1.32。該公司的 50 日移動平均價為 13.90 美元，200 日移動平均價為 12.52 美元。</p>
</div><p>Agenus (NASDAQ:AGEN - Get Free Report) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.58) by $0.54. The firm had revenue of $28.01 million during the quarter, compared to analyst estimates of $40.70 million. On average, sell-side analysts expect that Agenus Inc. will post -10.73 EPS for the current year.</p>
<div class="lb-trans"><p>Agenus（納斯達克：AGEN - 獲取免費報告）最近發佈了其財報，日期為 5 月 7 日。這家生物技術公司在該季度報告中每股虧損 3.04 美元，超過了每股虧損 3.58 美元的分析師預期。該公司在該季度的營收為 2,801 萬美元，低於分析師預期的 4,070 萬美元。賣方分析師平均預計，Agenus Inc.今年將實現每股盈利-10.73 美元。</p>
</div><h2>Agenus Profile (Free Report)</h2>
<div class="lb-trans"><h2>Agenus 簡介（免費報告）</h2>
</div><p>Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.</p>
<div class="lb-trans"><p>Agenus Inc.是一家臨牀階段的生物技術公司，致力於在美國和國際市場發現和開發免疫腫瘤學產品。該公司提供 Retrocyte Display，一種用於識別全人類和人源化單克隆抗體的抗體表達平台；以及展示技術。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Agenus</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>Why Call Options Volume for These 2 Stocks Spiked Together</li>
<li>What is Put Option Volume?</li>
<li>MarketBeat Week in Review – 7/22 - 7/26</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們比 Agenus 更喜歡的五支股票</li>
<li>除了喝咖啡，還有三種投資方式</li>
<li>為什麼這兩支股票的認購期權交易量會同時激增</li>
<li>什麼是認沽期權交易量？</li>
<li>MarketBeat 周評 - 7/22 - 7/26</li>
<li>零售投資者如何交易多倫多證券交易所（TSX）？</li>
<li>3M 公司的業績出人意料並加速反彈：現在入市為時尚早</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUdFTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AGEN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ 625,000% Gain (From Crypto Swap Profits)(Ad)</p>
<div class="lb-trans"><p>→ 625,000% 收益（來自加密交易利潤）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODI4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8828&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Agenus right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1,000 美元購買 Agenus 股票？</h2>
</div><p>Before you consider Agenus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Agenus 股票之前，您可能需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高且表現最佳的研究分析師以及他們向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户在更廣泛市場注意之前購買的股票...而 Agenus 不在這份名單上。</p>
</div><p>While Agenus currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Agenus 目前在分析師中的評級為 “持有”，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

阿卡迪亞資產管理公司購買了 720,629 股安帝君斯公司（NASDAQ:AGEN）的股票